Source:http://linkedlifedata.com/resource/pubmed/id/15176685
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2004-6-4
|
pubmed:abstractText |
A randomised double-blind placebo-controlled study was designed to evaluate the effects of a semisynthetic macrolide antibiotic, clarithromycin, on bronchial hyperresponsiveness to methacholine in patients with a diagnosis of asthma. Adult asthma patients undergoing treatment with budesonide 400 microg b.i.d. and salbutamol 200 microg p.r.n. less than twice weekly were studied. Arm A (16 males/six females, aged 48 +/- 16 yrs) received clarithromycin 250 mg b.i.d. for 8 weeks, arm B (eight males/12 females, aged 42 +/- 12 yrs) clarithromycin 250 mg t.id. and arm C (six males/15 females, aged 41 +/- 16 yrs) placebo dextrose tablets. Bronchial hyperresponsiveness was quantified by measurement of the provocative dose of methacholine causing a 20% fall in forced expiratory volume in one second (PD20). Median (interquartile range) PD20 in the three groups before and after treatment with clarithromycin were: arm A: 0.3 (0.1-1) and 1.3 (0.6-2) mg; arm B: 0.4 (0.1-0.9) and 2 (2-2) mg; and arm C: 0.4 (0.1-0.9) and 0.3 (0.1-0.6) mg, respectively. Serum free cortisol levels were determined and remained unchanged from baseline in the clarithromycin-treated patients. It is concluded that clarithromycin reduces the degree of bronchial hyperresponsiveness in patients with asthma.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0903-1936
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
714-7
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:15176685-Adult,
pubmed-meshheading:15176685-Anti-Bacterial Agents,
pubmed-meshheading:15176685-Asthma,
pubmed-meshheading:15176685-Bronchial Hyperreactivity,
pubmed-meshheading:15176685-Bronchial Provocation Tests,
pubmed-meshheading:15176685-Bronchoconstrictor Agents,
pubmed-meshheading:15176685-Clarithromycin,
pubmed-meshheading:15176685-Double-Blind Method,
pubmed-meshheading:15176685-Female,
pubmed-meshheading:15176685-Forced Expiratory Volume,
pubmed-meshheading:15176685-Humans,
pubmed-meshheading:15176685-Male,
pubmed-meshheading:15176685-Methacholine Chloride,
pubmed-meshheading:15176685-Middle Aged,
pubmed-meshheading:15176685-Spirometry,
pubmed-meshheading:15176685-Time Factors,
pubmed-meshheading:15176685-Treatment Outcome
|
pubmed:year |
2004
|
pubmed:articleTitle |
Clarithromycin reduces the severity of bronchial hyperresponsiveness in patients with asthma.
|
pubmed:affiliation |
10th Respiratory Dept, Athens Chest Hospital, Athens, Greece. ealexop@yahoo.com
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|